Health Care › Surgical And Medical Instruments And Apparatus
IDXG Stock Price Correlated With Interpace Diagnostics Financials
External Links ⌄
Income Statement
Cash Flow
Balance Sheet
IDXG Income Statement
Enable JavaScript and reload
Revenue, Net:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
IDXG Cash Flow
Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:
IDXG Balance Sheet
Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:
COMPANY PROFILE
INTERPACE
BIOSCIENCES, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular
information in thousands, except per share amounts)
1.
OVERVIEW
Nature
of Business
Interpace
Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services
along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services.
The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the
latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics
testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances
personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into
their drug development and clinical trial programs.
COVID-19
pandemic
The
COVID-19 pandemic, together with related precautionary measures, continues to impact portions of the regions in which we operate. These
regions are attempting to address the COVID-19 pandemic in varying ways, including stay-at-home orders, temporarily closing businesses,
restricting gatherings, restricting travel, and mandating social distancing and face coverings. The level and nature of the disruption
caused by COVID-19 is unpredictable, may be cyclical and long-lasting and may vary from location to location.
The
continuing impact that the COVID-19 pandemic will have on our operations, including duration, severity and scope, remains highly uncertain
and cannot be fully predicted at this time. While we believe we have generally recovered from the adverse impact that the COVID-19 pandemic
had on our business during 2020, we believe that the COVID-19 pandemic could continue to adversely impact our results of operations,
cash flows and financial condition in the future.
We
continue to monitor the COVID-19 pandemic and the guidance that is being provided by relevant federal, state and local public health
authorities and may take additional actions based upon their recommendations. It is possible that we may have to make adjustments to
our operating plans in reaction to developments that are beyond our control.
Lab
closures experienced thus far by the Company have consisted of periodic, temporary work stoppages to clean and disinfect the labs. However,
this could change in the future based upon conditions caused by the pandemic. Inflation and supply chain disruptions, whether caused
by restrictions or slowdowns in shipping or logistics, increases in demand for certain goods used in our operations, or otherwise, could
impact our operations in the near term. For the foreseeable future, however, we do not anticipate supply chain shortages of critical
supplies.
We
have contingency plans in place and will continue to monitor and update them in order to mitigate pandemic-related, adverse financial
impacts upon our business.
Transition
costs
Transition
expenses are primarily related to the Rutherford, New Jersey lab closing and subsequent move to Morrisville, North Carolina, which was
completed during the first half of Fiscal 2021, as well as other cost-saving initiatives consisting primarily of reductions in headcount
and the implementation of a new laboratory information system. To optimize the operations of laboratory operations within our pharma
services, we transitioned activities from the Rutherford facility to our Morrisville facility. The transition included the transfer of
personnel, expansion of the Morrisville facility and validation of transferred processes.
BIOSCIENCES, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular
information in thousands, except per share amounts)
1.
OVERVIEW
Nature
of Business
Interpace
Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services
along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services.
The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the
latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics
testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances
personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into
their drug development and clinical trial programs.
COVID-19
pandemic
The
COVID-19 pandemic, together with related precautionary measures, continues to impact portions of the regions in which we operate. These
regions are attempting to address the COVID-19 pandemic in varying ways, including stay-at-home orders, temporarily closing businesses,
restricting gatherings, restricting travel, and mandating social distancing and face coverings. The level and nature of the disruption
caused by COVID-19 is unpredictable, may be cyclical and long-lasting and may vary from location to location.
The
continuing impact that the COVID-19 pandemic will have on our operations, including duration, severity and scope, remains highly uncertain
and cannot be fully predicted at this time. While we believe we have generally recovered from the adverse impact that the COVID-19 pandemic
had on our business during 2020, we believe that the COVID-19 pandemic could continue to adversely impact our results of operations,
cash flows and financial condition in the future.
We
continue to monitor the COVID-19 pandemic and the guidance that is being provided by relevant federal, state and local public health
authorities and may take additional actions based upon their recommendations. It is possible that we may have to make adjustments to
our operating plans in reaction to developments that are beyond our control.
Lab
closures experienced thus far by the Company have consisted of periodic, temporary work stoppages to clean and disinfect the labs. However,
this could change in the future based upon conditions caused by the pandemic. Inflation and supply chain disruptions, whether caused
by restrictions or slowdowns in shipping or logistics, increases in demand for certain goods used in our operations, or otherwise, could
impact our operations in the near term. For the foreseeable future, however, we do not anticipate supply chain shortages of critical
supplies.
We
have contingency plans in place and will continue to monitor and update them in order to mitigate pandemic-related, adverse financial
impacts upon our business.
Transition
costs
Transition
expenses are primarily related to the Rutherford, New Jersey lab closing and subsequent move to Morrisville, North Carolina, which was
completed during the first half of Fiscal 2021, as well as other cost-saving initiatives consisting primarily of reductions in headcount
and the implementation of a new laboratory information system. To optimize the operations of laboratory operations within our pharma
services, we transitioned activities from the Rutherford facility to our Morrisville facility. The transition included the transfer of
personnel, expansion of the Morrisville facility and validation of transferred processes.
Free historical financial statements for Interpace Diagnostics Group Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 32 quarters since 2016. Compare with IDXG stock chart to see long term trends.
Data imported from Interpace Diagnostics Group Inc SEC filings. Check original filings before making any investment decision.